FDALabel:药品说明书全文检索
正文 · 中文译文
FDALabel:药品说明书全文检索 用于检索FDA批准药品说明书文件的网络应用程序。 生物信息学工具 少数民族人群药物基因组学信息数据库(dbPGxEMP) 从头组装质量评估工具(dnAQET) FDALabel:药品说明书全文检索 ArrayTrack™ HCA-PCA独立软件包 决策森林 内分泌干扰物知识库(EDKB) 雌激素活性数据库(EADB) 肝毒性知识库(LTKB) DICTrank数据集 DIRIL数据集 MAQC/SEQC Mold2 FDALabel数据库访问 FDALabel数据库概述 潜在用户 药品说明书中包含哪些内容? 数据库功能 实时查询 更新与统计 用户指南 附加信息 其他资源 参考文献 联系方式 免责声明 如需使用FDALabel,请选择以下链接或将URL复制到浏览器中: https://nctr-crs.fda.gov/fdalabel/ui/search FDALabel版本2.11 如需提供反馈或请求协助,请联系: NCTR生物信息学 FDALabel数据库概述 FDALabel数据库是一个基于网络的应用程序,用于对超过160,000份人用处方药、生物制品、非处方药(OTC)及兽药说明书文件进行可定制检索。FDALabel的数据来源是FDA的结构化产品标签(SPL)档案,1-3该档案存储由制造商提交的说明书文件。FDALabel以安全的三层应用程序架构实现,后端采用Oracle数据库。 下表列出了FDALabel中几种常见说明书类型的数量。 截至2026年11月12日的标签类型数量 人用非处方药*101,701 人用处方药和生物制品**60,113 动物处方药和动物非处方药产品3,553 * 包括通过新药申请(NDA)、简化新药申请(ANDA)或非处方药专论系统获批上市的人用非处方药。 ** 包括药品、治疗性生物制品、疫苗、血浆衍生物、变应原制品(标准化和非标准化)、细胞治疗以及获许可的最小操作细胞。 潜在用户 您可以在许多情况下使用FDALabel数据库中的丰富信息,包括作为医疗保健提供者快速获取药物适应症和警告,作为制药公司用于药物开发,或作为研究药物安全性的研究人员。例如,近期出版物描述了如何利用药品标签中的信息来辅助和促进药物重定位4,以及在精准医学、药物安全和监管科学中的应用。5-7另一篇出版物展示了如何开发一种使用FDA批准药品标签的系统分类方案来评估药物引起药物性肝损伤的潜力,从而说明了FDALabel数据库的实用性。8 数据库中包含哪些药品标签? FDALabel数据库包括以下类型的标签: 人用处方药和生物制品标签,包括处方信息、患者标签以及纸盒和容器标签:药品 治疗性生物制品和单克隆抗体 疫苗 其他生物制品(例如血液制品、过敏原制品、细胞治疗) 人用非处方(OTC)标签:已批准药物 按专论系统上市的产品 未经批准的顺势疗法处方药和顺势疗法非处方产品 动物处方药和动物非处方产品标签 其他类型的标签:医疗器械 膳食补充剂 化妆品 医疗食品 已批准的人用处方药和生物制品的处方信息包含安全有效使用该产品所需的基本科学信息摘要。它包括适应证、剂量和给药方法、禁忌证、警告和注意事项、不良反应、药物相互作用、特殊人群用药信息以及其他对医疗保健提供者重要的信息9。相关的患者标签(例如患者信息、用药指南、使用说明)面向患者、家属或照护者。相关的容器和外包装标签传达从初始处方、采购、产品调配和分发到给予患者时对药物安全使用至关重要的信息。 已批准非处方药和按专论系统管理的非处方药的标签称为药物事实(Drug Facts)。药物事实包括有关药物用途和作用、警告、使用说明以及其他信息。 顺势疗法处方药和顺势疗法非处方药未经FDA批准,但允许上市销售。这些未经批准的产品仅有最低限度的标签要求。 数据库功能 能够对整个标签或标签的特定部分/小节进行全文检索。 通过以下功能执行复杂查询,可检索:文件类型 上市类别 处方信息特定部分的存在或其中的文本(例如,黑框警告、适应症与用法、剂量与给药方法、警告与注意事项、不良反应、药物相互作用) SPL标识符(例如,产品NDC代码、UNII、SETID) 上市开始/结束日期 药理学类别 结果包含指向SPL文件、DailyMed、Drugs@FDA和橙皮书的直接链接。 将标签检索结果导出为电子表格格式,以便保存并在Excel中打开。 永久链接,允许用户保存查询并与同事共享。 FDALabel实时查询与使用案例 搜索功能 查询描述 查询* 结果** 标签全文检索[简单搜索] “急性肝衰竭” https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/106525 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/106525 标签全文检索[简单搜索] “呼吸抑制” https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/116786 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/116786 标签全文检索 [高级检索] 生物标志物“BRCA或BRAF” https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/116776https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/116776 标签章节 [简单检索]“糖尿病”位于适应症与用途内 https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/110855https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/110855 标签章节 [简单检索]“β受体阻滞剂”位于药物相互作用内 https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/110856 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/110856 标签章节 [高级检索]“妊娠或胎儿”位于黑框警告内 https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/110851 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/110851 MedDRA术语“急性肝衰竭[PT]及LLTs”https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/102842 https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/102842 药理类别5-羟色胺摄取抑制剂[MoA] https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/102754https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/102754 * 点击查询链接以查看、编辑和重复该查询 ** 点击结果链接以查看标签结果、下载完整结果并查看查询永久链接 要使用FDALabel,请选择下方链接或将URL复制到浏览器中: https://nctr-crs.fda.gov/fdalabel/ui/search 更新与统计 FDALabel 中的药品说明书数据每周更新。 用户指南 FDALabel 手册 FDALabel 快速入门指南 简单检索指南 高级检索指南 查询逻辑指南 附加信息 FDALabel 演示(视频)| 2021 年全球监管科学峰会(GSRS) FDALabel 报告(PDF)| 2021 年全球监管科学峰会(GSRS) 其他资源 药品批准与数据库 面向消费者的药品信息 面向产业界的信息 | 药品 说明书信息 | 药品 面向患者和提供者的上市后药品安全信息 处方药说明书资源 参考文献 结构化产品说明书资源 FDA 在线说明书库 DailyMed Fang H., Harris S.C., Liu Z., Thakkar S., Yang J., Ingle T., Xu J., Lesko L., Rosario L., and Tong W. "FDALabel for drug repurposing studies and beyond." Nature Biotechnology. 2020, 38:1378-1379. 摘要 Ying L., Liu Z., Fang H., Kusko R., Wu L., Harris S., and Tong W. "Text summarization with ChatGPT for drug labeling documents." Drug Discovery Today. 2024, 29(6), 104018. 摘要 Mehta D., Uber R., Ingle T., Li C., Liu Z., Thakkar S., Ning B., Wu L., Yang J., Harris S.C., Zhou G., Xu J., Tong W., Lesko L., and Fang H. "Study of Pharmacogenomic Information in FDA-approved Drug Labeling to Facilitate Application of Precision Medicine." Drug Discovery Today. 2020, 25(5), 813-820. 摘要 Wu L., Ingle T., Liu Z., Zhao-Wong A., Harris S.C., Thakkar S., Zhou G., Yang J., Xu J., Mehta D., Ge W., Tong W., ang Fang H. “使用FDA批准药物标签和MedDRA研究严重药物不良反应。” BMC Bioinformatics. 2019, 20(97). 摘要 Fang H., Harris S.C., Liu Z., Zhou G., Zhang G., Xu J., Rosario L., Howard P.C., and Tong W. “FDA药物标签:促进精准医学、药物安全和监管科学的丰富资源。” Drug Discovery Today. 2016, 21(10):1566-1570. 摘要 Chen M.J., Vijay V., Shi Q., Liu Z.C., Fang H., and Tong W.D. “FDA批准药物标签用于药物性肝损伤研究。” Drug Discovery Today. 2011, 16(15-16):697-703. 摘要 21 CFR 201.57 联系信息 功能联系人 问题、建议或获取帮助:FDALabel支持 报告技术问题:NCTRBioinformaticsSupport@fda.hhs.gov 免责声明 数据来源 FDALabel的数据来源是DailyMed的结构化产品标签(SPL)档案,其中包含公司提交的最新标签文件(“使用中”标签)。在FDALabel上找到的SPL文件也可在DailyMed和FDA在线标签库中找到。 SPL与FDA批准标签之间的差异 SPL文件中的标签可能与Drugs@FDA上可获取的最新FDA批准标签不完全相同,且SPL文件的内容(包括SPL文件中的数据元素条目)未经FDA核实。例如: 输出页面中列出的剂型来源于数据标准手册(DSM)术语,可能与《美国药典》(USP)术语或FDA批准标签中使用的剂型术语不一致。 列出的上市日期可能并不总能准确代表产品首次上市的日期。 与最新的FDA批准标签相比,SPL文件可能包含细微变更(例如编辑性变更,如添加经销商名称)或正在接受FDA审查的中等变更(例如添加或加强警告或不良反应)。 有关可能导致SPL标签与最新FDA批准标签之间存在差异的标签变更类型的信息,请参见21 CFR 314.70、21 CFR 601.12以及《行业指南:对已批准NDA或ANDA的变更》。 由于FDALabel上的SPL文件可能与最新的FDA批准标签不完全相同,请访问以下网站获取最新的FDA批准标签: Drugs@FDA,用于人用处方药和生物制品以及根据NDA或ANDA批准的OTC药品; 生物制品与生产设施,用于人血和血液制品;血浆衍生物;疫苗、过敏原及细胞和基因治疗产品;以及由CBER根据NDA或ANDA监管的产品(例如,血浆容量扩充剂)。 PLR格式标签的产品标题搜索的局限性 由于SPL文档的结构方式,对PLR格式说明书的FDALabel产品标题检索(通过“标签部分”搜索框中的“产品标题”选项执行)可能会包含一些说明书,而所查询的文本并不在产品标题中。例如,产品标题检索可能会返回一些说明书,其中所查询的文本出现在亮点限制声明、首次美国批准或生物类似药产品的生物相似性声明中。 非处方药 许多非处方药(例如OTC药物)未经FDA审评和批准(例如根据最终专论或临时最终专论上市的药品);但是,如果这些OTC药物符合适用的OTC专论,则可以上市销售。在FDALabel中标记为“OTC专论最终”或“OTC专论非最终”的药品说明书未进行与专论一致性的核查。在FDALabel中检索“人用OTC药物”说明书会检索到作为OTC的非处方药以及药房柜台后有售的非处方产品(例如非处方胰岛素产品)。 MedDRA术语检索和报告 监管活动医学词典(MedDRA)是由人用药品技术要求国际协调理事会(ICH)制定的标准化医学术语集。FDALabel 中开发的 MedDRA 功能旨在促进对产品说明书中不良事件(AE)发生情况的研究。应注意,MedDRA 版本更新每半年进行一次,可能因映射变化或 MedDRA 术语的升级/降级而影响搜索结果。FDALabel 在新版本发布期间至少每年更新一次 MedDRA 术语。FDA 不要求在说明书中使用 MedDRA 术语描述 AE。因此,FDALabel 中的 MedDRA 术语搜索或报告可能无法代表说明书中所有 AE 概念。此外,说明书中出现 MedDRA 术语不一定指 AE(例如,MedDRA 术语可能对应适应证或患者合并症)。在应用 FDALabel 中的 MedDRA 功能时,定义了使用 MedDRA 进行自然语言处理(NLP)的具体规则(见 PDF)。标签文件(SPL:结构化产品标签)按照预定义的 MedDRA 规则以 MedDRA 最低层级术语(LLT)进行索引。从 SPL 中提取的 MedDRA LLT 被映射至首选术语(PT)以生成 MedDRA 报告。 为您提供的资源 关于国家毒理学研究中心 生物信息学工具 获取 NCTR 电子邮件更新 内容截至日期: 2026年11月12日 受监管产品 动物与兽医 生物制品 膳食补充剂 药物 医疗器械 动物细胞制品 过敏原制品 医学食品/饮料 非活性成分 主题 新兽药申请(NADA)
正文 · 英文原文
FDALabel: Full-Text Search of Drug Product Labeling Web-based application to search labeling documents of FDA-approved drug products. Bioinformatics Tools Database of Pharmacogenomic Information in Ethnic Minority Populations (dbPGxEMP) de novo Assembly Quality Evaluation Tool (dnAQET) FDALabel: Full-Text Search of Drug Product Labeling ArrayTrack™ HCA-PCA Standalone Package Decision Forest Endocrine Disruptor Knowledge Base (EDKB) Estrogenic Activity Database (EADB) Liver Toxicity Knowledge Base (LTKB) DICTrank Dataset DIRIL Dataset MAQC/SEQC Mold2 FDALabel Database Access Overview of FDALabel Database Potential Users What is Included in Drug Labeling? Database Features Live Queries Updates and Statistics User Guides Additional Information Other Resources References Contact Information Disclaimer To use FDALabel, select the link below or copy URL into browser: https://nctr-crs.fda.gov/fdalabel/ui/search FDALabel Version 2.11 Provide feedback or request assistance by contacting: NCTR Bioinformatics Overview of FDALabel Database The FDALabel Database is a web-based application used to perform customizable searches of over 160,000 human prescription, biological, over-the-counter (OTC), and animal drug labeling documents. The source of FDALabel's data is the FDA's Structured Product Labeling (SPL) archive,1-3 which stores labeling documents submitted by manufacturers. FDALabel is implemented as a secure three-tier application with an Oracle database. The following table lists the count of several common labeling types in FDALabel. Labeling Types Number of Labeling as of November 12, 2026 Human OTC Drugs*101,701 Human Prescription Drugs and Biological Products**60,113 Animal Prescription and Animal OTC Products3,553 * Includes Human OTC drugs approved for marketing through a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or the OTC monograph system. ** Includes drug products, therapeutic biologics, vaccines, plasma derivatives, allergenics (standardized and non-standardized), cellular therapy, and licensed minimally manipulated cells. Potential Users You can use the wealth of information in the FDALabel Database in many cases including as a healthcare provider for quick access to drug indications and warnings, as a pharmaceutical company for drug development, or as a researcher studying drug safety. For example, recent publications describe how information in drug labeling can be used to aid and facilitate drug repurposing4 as well as applications in precision medicine, drug safety, and regulatory science.5-7 Another publication demonstrated how a systematic classification scheme using FDA-approved drug labeling was developed to assess a drug’s potential for drug-induced liver injury, thus illustrating the utility of FDALabel Database.8 What drug labeling is included in the database? The FDALabel Database includes the following types of labeling: Human prescription drug and biological product labeling including prescribing information, patient labeling, and carton and container labeling: Drug products Therapeutic biologics and monoclonal antibodies Vaccines Other biological products (e.g., blood products, allergenics, cellular therapy) Human over-the-counter (OTC) labeling: Approved drugs Products marketed under the monograph system Unapproved homeopathic prescription and homeopathic OTC products Animal prescription and animal OTC product labeling Other types of labeling: Medical devices Dietary supplements Cosmetics Medical foods Prescribing information for approved human prescription drug and biological products contains a summary of the essential scientific information needed for the safe and effective use of the product. It includes indications, dosage and administration, contraindications, warnings and precautions, adverse reactions, drug interactions, information about use in specific populations, and other important information for healthcare providers9. Associated patient labeling (e.g., Patient Information, Medication Guide, Instructions for Use) are directed to the patient, family, or caregiver. Associated container and carton labeling communicate information that is critical to the safe use of a medication from the initial prescription, to procurement, to preparation and dispensing of the product, to the time it is given to the patient. Labeling for approved OTC drugs and OTC drugs under the monograph system is called Drug Facts. Drug Facts includes information about the purpose and use of the drug, warnings, directions for use, and other information. Homeopathic prescription and homeopathic OTC drugs are not approved by the FDA but are allowed to be marketed. There are minimal labeling requirements for these unapproved products. Database Features Ability to conduct full text searches of the entire labeling or specific sections/subsections of labeling. Perform complex queries with functions that allow searching for: Document types Marketing categories Presence of, or text within, specific sections of the prescribing information (e.g., BOXED WARNING, INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DRUG INTERACTIONS) SPL identifiers (e.g., Product NDC Codes, UNIIs, SETIDs) Market start/end date Pharmacologic Classes Results include direct links to the SPL document, DailyMed, Drugs@FDA, and Orange Book. Export labeling results to a spreadsheet format to save and open in Excel. Permanent links that allow users to save and share queries with colleagues. FDALabel Live Queries and Use Cases Search FunctionQuery Description Query*Result** Labeling Full Text Search [Simple Search] “Acute liver failure” https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/106525 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/106525 Labeling Full Text Search [Simple Search] “Respiratory depression” https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/116786 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/116786 Labeling Full Text Search [Advanced Search] Biomarker “BRCA or BRAF” https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/116776https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/116776 Labeling Section(s) [Simple Search] "Diabetes” within INDICATIONS AND USAGE https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/110855https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/110855 Labeling Section(s) [Simple Search]"Beta blocker" within DRUG INTERACTIONS https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/110856 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/110856 Labeling Section(s) [Advanced Search] “Pregnancy or fetus” within BOXED WARNING https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/110851 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/110851 MedDRA Terms"Acute hepatic failure [PT] and LLTs"https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/102842 https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/102842 Pharmacologic Class(es)Serotonin Uptake Inhibitors [MoA] https://nctr-crs.fda.gov/fdalabel/ui/search/spl-summaries/criteria/102754https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/102754 * Click the Query link to view, edit, and repeat the query ** Click the Result link to view labeling results, download full results, and view the query permanent link To use FDALabel, select the link below or copy URL into browser: https://nctr-crs.fda.gov/fdalabel/ui/search Updates and Statistics Drug Labeling Data within FDALabel is updated weekly. User Guides FDALabel Handout FDALabel Quick Start Guide Simple Search Guide Advanced Search Guide Query Logic Guide Additional Information FDALabel Demo (video) | 2021 Global Summit on Regulatory Science (GSRS) FDALabel Presentation (PDF) | 2021 Global Summit on Regulatory Science (GSRS) Other Resources Drug Approvals and Databases Drug Information for Consumers Information for Industry | Drugs Labeling Information | Drug Products Postmarket Drug Safety Information for Patients and Providers Prescription Drug Labeling Resources References Structured Product Labeling Resources FDA Online Label Repository DailyMed Fang H., Harris S.C., Liu Z., Thakkar S., Yang J., Ingle T., Xu J., Lesko L., Rosario L., and Tong W. "FDALabel for drug repurposing studies and beyond." Nature Biotechnology. 2020, 38:1378-1379. Abstract Ying L., Liu Z., Fang H., Kusko R., Wu L., Harris S., and Tong W. "Text summarization with ChatGPT for drug labeling documents." Drug Discovery Today. 2024, 29(6), 104018. Abstract Mehta D., Uber R., Ingle T., Li C., Liu Z., Thakkar S., Ning B., Wu L., Yang J., Harris S.C., Zhou G., Xu J., Tong W., Lesko L., and Fang H. "Study of Pharmacogenomic Information in FDA-approved Drug Labeling to Facilitate Application of Precision Medicine." Drug Discovery Today. 2020, 25(5), 813-820. Abstract Wu L., Ingle T., Liu Z., Zhao-Wong A., Harris S.C., Thakkar S., Zhou G., Yang J., Xu J., Mehta D., Ge W., Tong W., ang Fang H. "Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA." BMC Bioinformatics. 2019, 20(97). Abstract Fang H., Harris S.C., Liu Z., Zhou G., Zhang G., Xu J., Rosario L., Howard P.C., and Tong W. “FDA Drug Labeling: Rich Resources to Facilitate Precision Medicine, Drug Safety, and Regulatory Science.” Drug Discovery Today. 2016, 21(10):1566-1570. Abstract Chen M.J., Vijay V., Shi Q., Liu Z.C., Fang H., and Tong W.D. "FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury." Drug Discovery Today. 2011, 16(15-16):697-703. Abstract 21 CFR 201.57 Contact Information FunctionsContacts Questions, Suggestions, or Get Assistance: FDALabel Support Report Technical Problems: NCTRBioinformaticsSupport@fda.hhs.gov Disclaimer Data Source The source of FDALabel’s data is DailyMed's Structured Product Labeling (SPL) archive which contains the most recent labeling documents submitted by companies ("in use" labeling). The SPL documents found on FDALabel are also found on DailyMed and FDA Online Label Repository. Differences Between SPL and FDA-Approved Labeling The labeling in the SPL documents may not be identical to the most recent FDA-approved labeling available at Drugs@FDA, and the contents of the SPL documents (including data element entries in the SPL files) have not been verified by the FDA. For example: The dosage form(s) listed in the output page are derived from the Data Standards Manual (DSM) terminology and may not be consistent with United States Pharmacopeia (USP) terminology or dosage forms terminology used in FDA-approved labeling. The marketing date(s) listed may not always accurately represent the date that the product was first marketed. Compared with the most recent FDA-approved labeling, the SPL document may contain minor changes (e.g., editorial changes such as adding a distributor’s name) or moderate changes that are undergoing FDA review (e.g., added or strengthening a warning or adverse reaction). For information regarding types of changes to labeling that may result in differences between the SPL labeling from the most recent FDA-approved labeling, see 21 CFR 314.70, 21 CFR 601.12, and the Guidance for Industry: Changes to an Approved NDA or ANDA. Because the SPL documents on FDALabel may not be identical to the most recent FDA-approved labeling, visit the following sites for the most current FDA-approved labeling: Drugs@FDA for human prescription drug and biological products and for OTC drugs approved under an NDA or ANDA; Biologics Products & Establishments for human blood and blood products; plasma derivatives; vaccine, allergenic, and cellular and gene therapy products; and products regulated by CBER under an NDA or ANDA (e.g., Plasma Volume Expanders). Limitations of Product Title Search of PLR Format Labeling Because of how SPL documents are structured, an FDALabel product title search of PLR format labeling (performed via the "Product Title" option in the Labeling Section(s) search box) may include some labeling for which the queried text is not in the product title. For example, the product title search may result in some labeling that have the queried text appearing in the Highlights Limitation Statement, the Initial U.S. Approval, or the biosimilarity statement for biosimilar products. Nonprescription Drugs Many nonprescription drugs (e.g., OTC drugs) are not reviewed and approved by the FDA (e.g., drugs marketed under a final monograph or a tentative final monograph); however, these OTC drugs may be marketed if they comply with applicable OTC monographs. The labeling for drugs marked "OTC monograph final" or "OTC monograph not final" in FDALabel are not checked for conformance to the monograph. A search for the "Human OTC Drugs" labeling in FDALabel retrieves nonprescription drugs that are OTC as well as nonprescription products available behind the pharmacy counter (e.g., nonprescription insulin products). MedDRA Terms Search and Report The Medical Dictionary for Regulatory Activities (MedDRA) is a standardized medical terminology developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The MedDRA features developed in FDALabel are intended to facilitate the study of adverse event (AE) occurrences in product labeling. It should be noted that MedDRA version updates, which occur on a biannual basis, may affect search results due to changes in mapping or promotion/demotion of MedDRA terms. FDALabel updates MedDRA terminology at least once a year during a new version release. The FDA does not require AEs to be described with MedDRA terminology in labeling. Thus, a MedDRA term search or report in FDALabel may not represent all AE concepts represented in labeling. Furthermore, the presence of a MedDRA term in labeling may not necessarily refer to an AE (e.g., MedDRA terms may correspond to indications or patient comorbidities). During the application of the MedDRA features in FDALabel, specific rules (see PDF) were defined for applying Natural Language Processing (NLP) using MedDRA. Labeling documents (SPL: Structured Product Labeling) are indexed by MedDRA Lowest Level Terms (LLTs) following the predefined MedDRA rules. MedDRA LLTs, extracted from a SPL, are mapped to Preferred Terms (PTs) for the MedDRA report. Resources For You About the National Center for Toxicological Research Bioinformatics Tools Get Email Updates for NCTR Content current as of: 11/12/2026 Regulated Product(s) Animal & Veterinary Biologics Dietary Supplements Drugs Medical Devices Animal Cell-Based Products Allergenics Medical Food/Beverage Inactive Ingredient Topic(s) New Animal Drug Application (NADA)